Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
Submitted by
admin
on April 15, 2015 - 9:28am
Source:
Fierce Pharma Marketing
News Tags:
JNJ
Invokana
SGLT2 inhibitor
diabetes
Boehringer Ingelheim
Eli Lilly
Jardiance
Glyxambi
Headline:
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
Do Not Allow Advertisers to Use My Personal information
